VACCINE INSIGHTS

In this issue, Ravi Ganapathy (IVI) offers a comprehensive look at continuous vaccine manufacturing, mapping the bottlenecks, technologies, and regulatory considerations shaping the field. Plus, contributors from CEPI, the IVI Europe Regional Office, and the Novo Nordisk Foundation for Vaccines & Immunity make the case for a formalised Nordic vaccine collaboration.

"Preparedness cannot be built during a crisis, and existing Nordic capabilities should be harmonised during peacetime." – Catherine Fleck-Vidal, International Vaccine Institute Europe Regional Office

"The industry's shift toward process intensification represents not only a technological advancement but also a fundamental transformation in vaccine manufacturing practices – from distinct batch processes to interconnected, data-driven, continuous systems." – Ravi Ganapathy, Senior Director of Vaccine Process Development, IVI

In this issue, we meet members of the Vaccine Insights editorial advisory board, including Senior Editor, Ingrid Kromann (CEPI). Plus, we get the latest on oral vaccine delivery with Vaxart's Sean Tucker and explore exciting new research into how mRNA vaccination affects antitumor immunity.

“Science and policy are inseparable; decisions in one domain reverberate across the other.”
– Ingrid Kromann, Senior Advisor, Process Development and Manufacturing, CEPI

“COVID-19 mRNA vaccination should be explicitly accounted for when interpreting oncology datasets from that period.”
– Adam Grippin, Physician-Scientist and Radiation Oncologist, MD Anderson Cancer Center

FEATURING

Issue Spotlight: Bioinformatics and AI/ML tools to streamline vaccine discovery, development, and manufacturing